Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04188483
Other study ID # ENT-SELENIUM-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 15, 2019
Est. completion date February 1, 2020

Study information

Verified date February 2020
Source Huazhong University of Science and Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is designed to assess whether selenium supplementation can boost the immunity response to influenza vaccination in healthy adults. This is a randomized, prospective study enrolling a total of 60 healthy subjects, 18-55 years old.


Description:

Background: Selenium is an essential trace element required for human health and wellbeing. Despite mouse studies and human clinical trial suggest selenium supplementation might enhance immunity, little is known for the effects of selenium supplementation on humoral immunity. Vaccination is the most effective medical intervention to prevent infections and to reduce disability and mortality associated with infectious disease. However, some individuals, in healthy or disease conditions, mount less effective humoral immune responses to vaccination. Therefore, new strategy to enhance humoral immunity upon vaccination is highly sought after. Using mouse models, we have observed that selenium supplementation significantly increased antigen-specific antibody responses. Thus, we hypothesize that selenium supplementation may be beneficial in enhancing humoral immunity in humans.

Objectives: To investigate whether selenium supplementation will boost the humoral response to influenza vaccination in healthy adults.

Design and trial size: This is a randomized prospective study. A total of 60 healthy subjects, 18-55 years old, will be enrolled in this study.

Intervention and duration: The enrolled subjects will be randomized into selenium supplementation and control group. The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. The control group will not receive selenium supplementation. Thirty days after allocation, both groups will receive standard seasonal influenza vaccination for the 2019-2020 season. Peripheral blood samples will be collected at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination).


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 1, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

18-55 years, healthy subjects

Exclusion Criteria:

1. With the history of selenium supplementation as taking supplementation products or living more than 2 years in selenium-enriched area;

2. Had the symptoms of selenium toxicity or serum selenium level greater than 328 µg/L;

3. With the history of the administration of influenza vaccine in past three years or allergic to influenza vaccine;

4. With any current immunologic disorders, including autoimmune and allergic diseases;

5. With any cardiovascular, metabolic, mental, or psychological disorders;

6. Pregnancy or breastfeeding;

7. With the history of infectious diseases including airway infections in past three months;

8. Who are currently participating in other clinical studies or who have participated in other clinical research within 90 days

Study Design


Intervention

Dietary Supplement:
Selenium Supplementation
The selenium supplementation group will receive 200 µg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
Biological:
Influenza vaccination
Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.

Locations

Country Name City State
China Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei

Sponsors (2)

Lead Sponsor Collaborator
Huazhong University of Science and Technology The University of Queensland

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The production of antigen-specific antibodies after vaccination Viral strain-specific antibodies in serum at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by hemagglutination inhibition (HAI) assay 60 days
Secondary Immune cell responses after selenium supplementation and vaccination Frequencies (%) of immune cells including T cells, B cells, monocytes, dendritic cells, NK cells in peripheral blood at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination)will be measured by flow cytometry. 60 days
Secondary Immune cytokine IFN-? after selenium supplementation and vaccination Levels of IFN-? in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by enzyme-linked immunosorbent assay (ELISA). 60 days
Secondary Immune cytokine IL-4 after selenium supplementation and vaccination Levels of IL-4 in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by enzyme-linked immunosorbent assay (ELISA). 60 days
Secondary Immune cytokine IL-10 after selenium supplementation and vaccination Levels of IL-10 in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by enzyme-linked immunosorbent assay (ELISA). 60 days
Secondary Immune cytokine IL-17A after selenium supplementation and vaccination Levels of IL-17A in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by enzyme-linked immunosorbent assay (ELISA). 60 days
Secondary Immune cytokine IL-21 after selenium supplementation and vaccination Levels of IL-21 in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by enzyme-linked immunosorbent assay (ELISA). 60 days
Secondary Selenium levels after selenium supplementation and vaccination Level of selenium in plasma at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination) will be measured by inductively coupled plasma mass spectrometry (ICP-MS). 60 days
See also
  Status Clinical Trial Phase
Completed NCT05509270 - Efficacy of Communication Modalities for Promoting Flu Shots N/A
Recruiting NCT05479370 - Immunogenicity Trial of 3 Influenza Vaccines Phase 3
Completed NCT03637036 - An Improvement Project Around Staffs' Influenza Vaccine Uptake N/A
Completed NCT01942824 - Adult Influenza Vaccination Text Message Reminders N/A
Completed NCT01009645 - The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination N/A
Completed NCT05783713 - Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study
Recruiting NCT03346772 - Study of Immune Responses to Influenza Vaccination Phase 4
Completed NCT03104790 - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls Phase 4
Completed NCT05836818 - PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED N/A
Completed NCT05785078 - Evaluation of a Flu Vaccination Program Directed at Pregnant Women Assisted at a Research Hospital in Italy.
Completed NCT04568785 - Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT01233804 - Opting In vs Opting Out N/A
Completed NCT04494581 - GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
Recruiting NCT04367883 - Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Completed NCT06300242 - Incentives for Influenza Vaccination N/A